Current Assets
Cash & Equivalents
Neurocrine Biosciences Cash & Equivalents decreased by 61.9% to $274.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 35.8%, from $202.10M to $274.50M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 30.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2012
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
Peer comparison
A universal metric for assessing a company's immediate financial health.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $371.20M | $314.30M | $344.00M | $278.00M | $171.10M | $220.00M | $270.70M | $111.60M | $168.20M | $301.70M | $259.10M | $404.30M | $147.70M | $357.10M | $241.00M | $202.10M | $272.00M | $348.20M | $721.00M | $274.50M |
| QoQ Change | — | -15.3% | +9.4% | -19.2% | -38.5% | +28.6% | +23.0% | -58.8% | +50.7% | +79.4% | -14.1% | +56.0% | -63.5% | +141.8% | -32.5% | -16.1% | +34.6% | +28.0% | +107.1% | -61.9% |
| YoY Change | — | — | — | — | -53.9% | -30.0% | -21.3% | -59.9% | -1.7% | +37.1% | -4.3% | +262.3% | -12.2% | +18.4% | -7.0% | -50.0% | +84.2% | -2.5% | +199.2% | +35.8% |
Range$111.60M – $721.00M
CAGR-6.2%
Avg YoY Growth+24.6%
Median YoY Growth-3.4%
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's cash & equivalents?
- Neurocrine Biosciences (NBIX) reported cash & equivalents of $274.50M in Q1 2026.
- How has Neurocrine Biosciences's cash & equivalents changed year-over-year?
- Neurocrine Biosciences's cash & equivalents increased by 35.8% year-over-year, from $202.10M to $274.50M.
- What is the long-term trend for Neurocrine Biosciences's cash & equivalents?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's cash & equivalents has grown at a 30.5% compound annual growth rate (CAGR), from $190.30M to $721.00M.
- What does cash & equivalents mean?
- Cash and highly liquid assets that can be converted to cash within 90 days.